Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Weekly Wrap 30 September

Grady Wulff
September 30, 2022

Morning Bell 30 September

Sophia Mavridis
September 30, 2022

Closing Bell 29 September

Grady Wulff
September 29, 2022

Morning Bell 29 September

Grady Wulff
September 29, 2022

Morning Bell 28 September

Grady Wulff
September 28, 2022

Closing Bell 27 September

Sophia Mavridis
September 27, 2022

Morning Bell 27 September

Sophia Mavridis
September 27, 2022

Closing Bell 26 September

Grady Wulff
September 26, 2022

Morning Bell 26 September

Grady Wulff
September 26, 2022

Morning Bell 23 September

Sophia Mavridis
September 23, 2022

Closing Bell 21 September

Grady Wulff
September 21, 2022

Morning Bell 21 September

Grady Wulff
September 21, 2022